+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 3Years - 25Years
All Genders
ID06927466

Study Evaluating Safety and Preliminary Effects of B019 Injection in Patients Aged 3 to 25 with Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia

Led by Shanghai Pharmaceutical Group Biological Therapy Technology Co., Ltd. · Updated on 2026-08-17

33

Participants Needed

8

Research Sites

78 weeks

Total Duration

AI-Summary

What This Trial Is About

This research aims to study the safety and tolerability of B019 injection in individuals diagnosed with relapsed or refractory B-cell acute lymphoblastic leukemia, a type of blood cancer. The trial focuses on patients between 3 and 25 years old who have experienced a return or resistance to previous treatments. The study is sponsored by Shanghai Pharmaceutical Group Biological Therapy Technology Co., Ltd. and is designed as a Phase 1 interventional trial to evaluate preliminary effects and safety. Participants will receive B019, a biological treatment given as an intravenous infusion of CAR T cells, with doses ranging from 1.0 106 to 10.0 106 CAR T cells per kilogram of body weight. This study uses a single-group design, meaning all participants receive the B019 infusion. The study includes a treatment phase and will continue monitoring for approximately two years to assess safety and treatment responses. During the trial, participants will be closely monitored for treatment-related adverse events for about two years. Researchers will also evaluate overall response to treatment within three months and overall survival during the two-year period. Pharmacokinetic measures such as Tmax and Cmax will be tracked to understand how the treatment behaves in the body. Participants will undergo regular assessments including laboratory tests and clinical evaluations to ensure safety and measure treatment effects throughout the study duration.

CONDITIONS

Brief Title

A Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of B019 Injection in Subjects With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia.

Research Team

J

Jing Chen

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here